Eppix Labs · US Research Library
Research Peptide Articles for US Laboratories
Written for labs in the United States. Articles keep what published studies report apart from what they have not shown, cite their sources, and most show the current certificate from our lab-results library for the compound they discuss. Nothing here is medical, dosing or administration guidance.
- articles
- 53
- sources cited
- 252
- last revised
- Oct 2
Recently Published
Jump to the full library ↓How to Vet a US Research Peptide Supplier in 2026: A 12-Point Checklist
Six analytical checks, three compliance signals and three practical ones, each answerable from a supplier's public pages before you order
Adam Reeves · Oct 2, 2026 · 5 min read · 3 sources
- 02Cagrilintide and Amylin Receptor Research: From Phase 2 to REDEFINE 1Compound Profiles · Sep 30, 2026 · 4 min
- 03Retatrutide in 2026: The TRIUMPH Phase 3 Program and What "Investigational" MeansCompound Profiles · Sep 28, 2026 · 5 min
- 04GLP-1, GIP and Glucagon Receptor Pharmacology: Mono-, Dual- and Triple-Agonist Peptides ComparedComparisons & Bench Methods · Sep 26, 2026 · 5 min
The Full Library
Certificate Checking
8- COAs & Testing
Purity vs Fill Accuracy: Why One Number Is Not Enough
Two independent measurements, and why suppliers publish only the first
- COAs & Testing
How to Verify a Peptide COA in Three Steps
A certificate is only worth what its verification path is worth, and most of the market has no verification path at all
- COAs & Testing
How to Spot a Fake Peptide COA: Seven Red Flags
Most bad certificates are not forgeries. They are real documents used to say something they do not say.
- COAs & Testing
How to Read a Certificate of Analysis
What each figure on a peptide COA proves — and what it does not
- COAs & Testing
Janoshik Testing Explained: How Every Eppix Batch Is Verified
What the laboratory measures, what its certificates report, and how to check any of ours on its database in two minutes
- COAs & Testing
HPLC Purity vs Net Peptide Content: Why a 99% Pure Vial Isn't 99% Peptide
One number describes what the detector saw, the other describes what the powder weighs, and only one of them belongs in a concentration calculation
- COAs & Testing
How to Read a Janoshik Certificate of Analysis: A Line-by-Line Guide for US Labs
Eight fields read top to bottom, and the six red flags that should stop a lab from using a lot
- COAs & Testing
Endotoxin Testing for Research Peptides: LAL, rFC and What an EU/mg Result Means
A contaminant HPLC cannot see, an assay family built on horseshoe crab blood and its recombinant replacement, and how to read the number they return
Bench Methods
4- Lab Practice
Peptide Reconstitution: The Laboratory Guide
Solvent choice, the arithmetic, and the handling errors that destroy material before an experiment starts
- Lab Practice
Peptide Storage and Shelf Life: The Laboratory Guide
Four degradation routes, two physical states, and why the dry solid is so much more forgiving than the solution
- Lab Practice
Shipping and Storing Lyophilized Peptides in the US: Heat, Transit Time and What to Do on Arrival
Dry material forgives a short ambient trip; days of heat, moisture and repeated warming are what to plan around
- Lab Practice
Peptide Reconstitution Math for the Lab: Concentration, Molarity, Dilution and Aliquots (Worked Examples)
Six steps from a lyophilized vial to labeled aliquots, each with its formula and a worked line you can check
FDA Status
5- Regulation
Are Peptides Legal in the US? A Plain-Language Overview
One statute does most of the work, "research use only" is a legal description rather than a disclaimer, and the July 2026 advisory vote changed less than it appeared to
- Regulation
The July 2026 FDA PCAC Peptide Vote: What It Does and Doesn't Change for US Researchers
Six of seven peptides won a non-binding recommendation for the 503A compounding list; for a laboratory buying research reagents, almost nothing moved
- Regulation
FDA's April 2026 Category 2 Removals Explained: 12 Peptides, Zero Approvals
Twelve peptides left the FDA's "do not compound" category because their nominations were withdrawn, which is a procedural change rather than a safety finding or a permission
- Regulation
What "Research Use Only" Actually Means in the US After the 2026 FDA Warning Letters
A label is one piece of evidence about intended use, and the March 2026 warning letters show the FDA reading the rest of the page
- Regulation
503A vs 503B vs RUO: The Three US Peptide Supply Chains, Compared
Two channels make drugs for patients and one sells chemicals to laboratories, and the rules, the oversight and the quality obligations differ accordingly
Compound Sourcing Profiles
21- COAs & Testing · Regulation
How to Choose a Peptide Supplier in the US: A Nine-Point Checklist
Nine things that are checkable before you spend anything, ordered by how much they tell you
- COAs & Testing · Regulation
How to Vet a US Research Peptide Supplier in 2026: A 12-Point Checklist
Six analytical checks, three compliance signals and three practical ones, each answerable from a supplier's public pages before you order
- Tissue Repair
BPC-157 in the US: Purity, Batch Certificates and What to Check
The most-searched research peptide in the US, and the four things worth checking before a vial is ordered
- Tissue Repair
TB-500 in the US: Synthetic Thymosin β4, Tested by Batch
What is actually in a TB-500 vial, why the naming confusion matters commercially, and how to verify a lot
- Metabolic & GLP-1
Retatrutide in the US: The Triple Agonist, and What Is Actually Published
A phase 2 compound with real trial data, no approval anywhere, and a research supply market moving faster than the evidence
- Metabolic & GLP-1
Tirzepatide in the US: Research-Grade, and How It Differs From the Pharmacy Product
The dual agonist with the deepest trial record in its class, and the distinction that matters when you buy it as a research material
- Metabolic & GLP-1
Semaglutide in the US: Research-Grade, Verified by Batch
The most-studied GLP-1 analog, the difference between a research vial and a prescription product, and what a certificate has to prove
- Tissue Repair
GHK-Cu in the US: The Copper Peptide, and Why the Copper Is the Hard Part
A tripeptide-copper complex with a fifty-year literature, and a quality question most certificates do not answer
- Growth Hormone
CJC-1295 and Ipamorelin in the US: The Blend, and What Each Half Does
Two compounds with different mechanisms sold in one vial, and the certificate problem that creates
- Metabolic & GLP-1 · Longevity
MOTS-c in the US: The Mitochondrial-Derived Peptide
A 16-residue peptide encoded in mitochondrial DNA, a decade of metabolic literature, and a July 2026 regulatory vote
- Longevity
NAD+ in the US: The Coenzyme, Not a Peptide
What NAD+ actually is, why it does not get a purity certificate that looks like a peptide certificate, and what the literature supports
- Tissue Repair · Immune & Inflammation
KPV in the US: The α-MSH Fragment in Inflammation Research
A tripeptide with a real preclinical literature, a July 2026 regulatory moment, and a supply market that has not caught up
- Growth Hormone
Ipamorelin in the US: The Selective Secretagogue
A pentapeptide whose defining property is what it does not do, and a certificate check that suits a small molecule
- Growth Hormone
Tesamorelin in the US: The GHRH Analog With Approved-Drug Data
The only compound in the GH-axis catalog with completed phase 3 trials, and why that does not transfer to a research vial
- Metabolic & GLP-1
Cagrilintide in the US: The Long-Acting Amylin Analog
The compound that made amylin the incretin field's second act, with published phase 2 data and no approval
- Cognitive
Selank in the US: The Tuftsin Analog From the Russian Literature
A heptapeptide with a real research program published almost entirely in one language, and what that means for reading the evidence
- Longevity
Epitalon in the US: The Telomerase Claim, Examined
A four-residue peptide carrying one of the strongest claims in the field, and the thinnest independent evidence base to support it
- Growth Hormone
Sermorelin in the US: GHRH(1-29), and the Approval That Was Withdrawn
The shortest fully active GHRH fragment, once an approved diagnostic and paediatric agent, now a research material again
- Immune & Inflammation
Thymosin Alpha-1 in the US: The Immune Peptide With Real Approvals Elsewhere
Approved in dozens of countries, never approved in North America, and sold here as a research material
- Metabolic & GLP-1 · Longevity
5-Amino-1MQ in the US: The NNMT Inhibitor That Is Not a Peptide
A small molecule in a peptide catalog, with a specific enzyme target and a certificate that should look different
- Metabolic & GLP-1
Eloralintide in the US: The Selective Amylin Agonist
The newest compound on the metabolic shelf, with a short but genuinely peer-reviewed public record
Head-to-Head
5- Tissue Repair
BPC-157 vs TB-500: The Research Comparison
Two compounds routinely sold as a pair, with different origins, different mechanisms and different kinds of evidence
- Metabolic & GLP-1
Retatrutide vs Tirzepatide: Triple Against Dual
One extra receptor, one approval, and a gap in trial depth that the receptor count does not close
- Metabolic & GLP-1
Semaglutide vs Tirzepatide: The Only Head-to-Head Trial in the Class
One receptor against two, and the rare case where the comparison was actually run rather than inferred
- Metabolic & GLP-1
GLP-1, GIP and Glucagon Receptor Pharmacology: Mono-, Dual- and Triple-Agonist Peptides Compared
One receptor, two or three: how semaglutide, tirzepatide and retatrutide differ at the receptor, and what that means for assay design
- Tissue Repair
TB-500 vs Thymosin Beta-4 vs Ac-SDKP: Three Molecules Sold Under One Name
A 43-residue protein, a seven-residue fragment and a four-residue cleavage product, and the one certificate line that tells them apart
Literature Summaries
10- Metabolic & GLP-1
Tirzepatide: A Research Literature Overview
Dual GIP / GLP-1 receptor agonist: published research summary
- Tissue Repair
BPC-157: A Research Literature Overview
Body Protection Compound: published preclinical research summary
- Tissue Repair · Regulation
BPC-157 in the US, 2026: Regulatory Status and What the Preclinical Literature Supports
Two regulatory steps in one year, neither of them an approval, and a preclinical literature that is large, rodent-heavy and concentrated in few hands
- Metabolic & GLP-1
Retatrutide in 2026: The TRIUMPH Phase 3 Program and What "Investigational" Means
Three company-reported phase 3 readouts, no approval, and why a topline press release is not yet a published trial
- Metabolic & GLP-1
Cagrilintide and Amylin Receptor Research: From Phase 2 to REDEFINE 1
How amylin receptors are built, what the long-acting analog was engineered to fix, and what its two key trials reported
- Growth Hormone
Tesamorelin as a Research Reference: What an FDA-Approved GHRH Analog Tells Us About the Class
The GHRH analog with a current approval behind it, and why that makes it a benchmark for receptor work rather than a shortcut
- Metabolic & GLP-1 · Longevity
MOTS-c Research Primer: A Mitochondrial-Encoded Peptide After the 2026 PCAC Review
Sixteen residues encoded in mitochondrial DNA, four papers that define the field, and the open questions a July 2026 vote did not answer
- Tissue Repair
GHK-Cu Research: Copper Complexation, Gene-Expression Data and the US Route Question
A copper-binding tripeptide with a long skin and wound literature, a large gene-expression dataset, and a US status that depends on the route
- Longevity
Epitalon and Telomerase Research: What the Studies Show and How to Verify Your Material
A four-residue peptide, one widely cited telomerase result, and a family of near-identical lookalikes that puts identity confirmation first
- Cognitive
Semax Research in the US: An ACTH(4-10) Analog After the 2026 PCAC Vote
A Russian-developed heptapeptide with one well-cited mechanistic paper, a thin Western literature, and an advisory vote in its favor
Explore by Subject
Each subject has its own page listing every article filed under it.
- Compound Profiles One peptide per article: the published studies, the gaps in them, and the certificate on file.29
- Comparisons & Bench Methods Paired compounds weighed on the literature, plus reconstitution arithmetic and storage conditions.9
- Verification & Lab Data Checking a certificate yourself: HPLC purity, fill quantity, lab confirmation, doctored reports.8
- FDA & Regulation Where research peptides sit under US federal law, and what recent FDA activity does not change.5
Who Writes These
Adam Reeves
Research Editor, Eppix Labs
Writes the compound profiles, the certificate-checking guides and the FDA reading in this library. The profile page sets out the scope of the role and lists every article under the byline.
View profile and articles →Editorial Rules
- Where an article summarizes published studies, claims carry a bracketed number that resolves to a References entry with a PubMed ID or a link to the source document.
- Where an article shows a certificate, it is drawn from the lab-results library with its batch number, rather than retyped into the text.
- Each article carries a named byline and the date it was first published.
- Statements about FDA status point to the agency or Federal Register document behind them.
- Laboratory research reference only. No dosing, administration or human-use guidance appears anywhere in the library.
Get the Research Digest
Periodic research summaries and new references, sent to the research list only.
Sold for in vitro laboratory research only. Not a drug, supplement or FDA-approved product, and not for human or veterinary use.